The consumer healthcare division of GlaxoSmithKline, which includes brands including Panadol and Aquafresh, has posted £2.5 billion (€2.9 billion) in sales in the third quarter of the group's financial year.
This is up 3% on a pro forma basis, at constant exchange rates.
If the positive impact of the merger with the Pfizer consumer healthcare business is included, sales are up 25% for the division in the period.
Reported group sales for the period were up 11% at constant exchange rates (+6% on a pro forma basis), to £9.4 billion (€10.89 billion).
'Good Progress'
“GSK has made further good progress in Q3, with sales growth across all three businesses, and we have today upgraded our full-year EPS guidance," commented Emma Walmsley, GSK chief executive.
"We also achieved a significant milestone with the completion of our new Consumer Healthcare Joint Venture with Pfizer, to create a new world leading consumer healthcare business.”
GSK anticipates 2019 adjusted EPS to be flat for the full year, at constant exchange rates.
© 2019 European Supermarket Magazine – your source for the latest retail news. Article by Stephen Wynne-Jones. Click subscribe to sign up to ESM: The European Supermarket Magazine.
